Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

IND Application Cleared for VOR33 in CD33+ Acute Myeloid Leukemia

The FDA cleared Vor Biopharma’s IND application for its hematopoietic cell therapy VOR33. This decision allows the company to initiate a phase I/IIa clinical...
WIB_icon

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
WIB_icon

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALL

A pediatric disease risk index (DRI) reported in Blood was capable of stratifying children with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...

What Is the Best Method for Cytoreduction in Patients With Acute Myeloid Leukemia and...

In patients with acute myeloid leukemia (AML), hyperleukocytosis is associated with the oncologic emergency leukostasis as well as inferior outcomes, but there are few...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia

Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...

Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS

Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...

Devimistat Receives FDA Fast Track Designation for AML

The FDA has granted fast track designation to devimistat for the treatment of acute myeloid leukemia (AML), clearing its manufacturer, Rafael Pharmaceuticals, to begin...

Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML

A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia...
Advertisement

Current Issue

March 2021 Volume 7 Issue 4

This issue examines blood services across the globe, the repercussions of increased patient access to medical information, and more.

Block title